Oncology therapy developer Recludix Pharma raised $60m in an Access Biotechnology-backed round while Stripe took part in digital payment technology developer Imprint's $38m series A.
Funding
Recludix Pharma, a US-based developer of small molecule cancer and inflammatory disease therapeutics, publicly launched yesterday with $60m in series A funding from investors including Access Biotechnology, a VC subsidiary of conglomerate Access Industries. Venture capital firms New Enterprise Associates and Westlake Village BioPartners also contributed to the round.
US-based digital payment and rewards technology developer Imprint raised $38m in series A funding from investors including online payment processor Stripe yesterday. The round was led by VC firm Kleiner…
